At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
dexpramipexoledrug
Likely dose
dexpramipexole 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Preliminary Efficacy of Dexpramipexole in Patients With Chronic Sinusitis With Nasal Polyps and Eosinophilia (CSNP-E)
In Brief
A Phase 2 clinical trial evaluating dexpramipexole for Chronic Sinusitis With Nasal Polyps and Eosinophilia. Completed, enrolled 20 participants across 7 sites.
Detailed Summary
Phase 2, open-label, multi-center study to evaluate the clinical effects of oral administration of dexpramipexole for 6 months in subjects with chronic sinusitis with nasal polyps and eosinophilia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartAug 2014
First PostedAug 2014
Primary CompletionDec 2016
Study CompletionJan 2017
TodayJul 2026
First PostedAug 15, 2014
Enrollment StartAug 1, 2014
Primary CompletionDec 14, 2016
Study CompletionJan 20, 2017
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 11.9 years ago
Interventions
dexpramipexoledrug
Dexpramipexole capsule-shaped film-coated tablets at the dose strength of 150 mg administered orally as 1 tablet twice daily (300 mg/day)